免费文献传递   相关文献

Evaluation for impacts of gut wall metabolism of multiple components in Chuanxiong Rhizoma during intestinal absorption with S9 incubation

肠S9温孵法研究川芎多成分肠吸收过程中的肠壁代谢



全 文 :2016
y

z ³
41
ų

}
Vol41,No.7 April,2016

”•)(
] 20151218

–—˜R
] 
ì(81274042)

™x?š
] 
89

Ž

‚‚öƒ„

€®……+*$†UB
,Tel:(010)84738629,Email:liuyang@bucmedncn

?š¢£
] 
-KR

‚‚€ö
,Email:yangwn0523@163com
²
S9
¶·«¬ ¡•–—²©ª
¸¹$±²ºP›
-KR

ST

UV

OWX

-YZ

89


}~!#$‘%

}~
100102)

›
] 
˜,×ÄÅÆ
(biopharmaceuticsclassificationsystem,BCS)
«¬$

²©ªµ~çƒ/¦Ù©ª¸¹$±²
ºP›’“

àï|«¬;ž…R²
S9
ì ¡$•–—±²ºP›Ön«¬

•Ö[Í
BCS
²©ªµ~çƒLªP›ò
ó

nž…R²
S9
ì ¡¢#¤Ön°ð¶·çƒ«¬


HPLC
‰2qç()

ìñ«¬•–—(琑2¶·íY±
 _

œæ*ú ¡¢#¤²
S9
¶·Y

a‰2qç*+±•–—çq$

€ ¡8

蕐–—m²ºP›

B

P›o_–—–

K¼è•–—¥m²ºP›

àï

€¯@[Í ¡±
BCS
²©ªµ~çƒMaì¥mÂ
²ºP›–—6záâ

§ì²ºP›–—±²©ªµ~{:/4jŽVH±çƒœ


œž
] 
˜,×ÄÅÆ

²
S9;
•–—
Evaluationforimpactsofgutwalmetabolismofmultiplecomponentsin
ChuanxiongRhizomaduringintestinalabsorptionwithS9incubation
YANGWenning,LIBo,WANGHao,CHENXinjing,YANGLiyuan,LIUYang
(BeijingUniversityofChineseMedicine,Beijing100102,China)
[Abstract] Theinformationofdrugdepositionintheintestineisrequiredinthestudyforthedrugabsorptioninbiopharmaceutics
classificationsystem(BCS)Toilustratetheimpactsofgutwalmetabolismontheabsorption,metabolismofmultiplecomponentsin
ChuanxiongRhizomaingutwalwastestedbyratS9incubationinvitroThechemicalfingerprinttechnologywasusedinthisstudyto
simultaneouslydetectmultiplecomponentsinChuanxiong,andpeakareasbeforeandafterS9incubationwerecomparedTheresults
showedthatsenkyunolideIandseveralconstituentsweremetabolizedbygutwal,andonenewmetabolitewasfoundedHowever,feru
licacidandothercompoundsremainedunchangedafterincubationTherefore,thesubsequentintestinalpermeabilityofmultiplecom
ponentsinChuanxiongthatwerenotmetabolizedintheintestinewassuggestedtobedetecteddirectlybyinsitusinglepassintestinal
perfusion(SPIP)Nonetheless,theintestinalpermeabilityoftheconstituentsthatweremetabolizedintheintestineshalbeexploredby
appropriateapproaches
[Keywords] biopharmaceuticsclassificationsystem;S9;multiplecomponents
doi:10.4268/cjcmm20160705
  
˜,×ÄÅÆ
(biopharmaceuticsclassifi
cationsystem,BCS)
Ÿ
1995
yG
GordonLAmidon
7§è
[1]
Hº#d

³´µÉÓ$±./‰Âý[

«¬,˜³´µ±œBðï²è

¿°Ul²Æ


²ÆG¬np¢è
[2]。

[3]


ʟ
²ºP›±òó

ì,˜±³´Å=áâO:/Ø>
6á,˜±²ºP›žŸ;žVH±çƒœ

$
,–—]•åæ-

•m+$,•–—¯°µ«¬±
·8811·
P^#è

²
S9
¶·«¬ ¡•–—²©ª¸¹$±²ºP›
r{

/—nž_‰2qç()±–ë

Iו–
—²ºP›¦O«¬ÉMn±

²ºP›çƒœ
B„•

@¸í}烜±«¬

²
S9
P›«¬
à²
S9
Ë)€ìÁU

œ–‹
[45],
ւOþB

M
6z

DöÖ²ºP›n•±½ë§G;$

 ¡
•¨_&…9ǎ˜ ¡
Ligusticumchuanxiong
Hort
±j©Ø@

ì|Ÿ

ŒÐ9
》。
Àíì 
¡±«¬•È$¿U[–—±P›
[68],
ìÓ¯°•
–—±P›çBkÚ
[9],
}Épž°ð«¬ ¡$
•–—±²ºP›øb]^”kÚ

àï

9«¬ì ¡¢#˜Ön«¬

‚ž…R²
S9
P›«¬

œV•–—‰2qç—à

4j²
S9
ì ¡$•–—±P›žŸ

¦§•@[Í ¡$•
–—²³´µâµ¬âߗà#G1i?W¬‰]

1 
ŠÌ
WATERS600
¤€(çÅÆ
(Milford,MA,
USA),
Ê
Delta600
A~•¬
2487
üVËÜð‚á


g0M•
Milennium32。115PK
žSf

\%
Sigma
DE
)。
 ¡Ž-ßàŸ23¦£¤,¥

23$A
,…Iáâ£7§<âÓÏ>•¨_&…9ǎ
˜ ¡
LChuanxiong
±j©Ø@

K¼ìH¤
(Aladdin,
‹¾
99%,
Þ<
F1110835g);
€ ¡8
I(
–†!ª\˜()BCDE

‹¾≥98%,Þ<
141027);
‡¨

(ç‹

‘%
Fisher
DE
);


(
ç‹

‘%
Fisher
DE
);
‹°¢

®¯¯
);
Óâ
Ãu•—à‹

SD
…R

²µ

°.
280~320g,
23–¢Sç
ƒ¶˜&(BCDE#G

íMŠ<
SCXK(
3

20110004,
¶˜³½Ÿ23$A,…烶˜1
ÂÈ´DM²8

•ÊŽò

úµÏš
12h/12h。
2 
œ
21 
˜¤ÙË
211 
 ¡¢#¤Ë)
 
Ö ¡Ž-
10051g,
Å
1L
%žï¢–G#Ö
15h,
ë¸Ä

ÄNÅ
1L
%žï¢Wº#Ö

ë¸Ä

V¬Ä¤¬Åb

â
êä
100mL
ßÁ$



ƒOÇÏäb:ž

212 
ìH¤˜¤ÙË
 
—`~c¼ÖK¼

€
 ¡8

ìH¤Ÿ
10mL
ßÁ$

‡¨˜7ÇÏ
•Þßžȕ
02g·L-1
±ìH¤˜¤

213 KCl
˜¤ÙË
 
Èî¼Ö
154mmol·L-1
KCl,
Å%žï¢
100mL
˜7˖
115%
±
KCl
˜
¤

;L)ž

214 20mmol·L-1HEPES
yÕ¤ÙË
 
Ö
20
mmol·L-1HEPES,154mmol·L-1KCl
L
100mL
ßÁ$

Źº¢ŸO¾›ØÎ


1mol·L-1
NaOH
˜Ï
pH
Ÿ
741,
¹<

22 
²
S9
Ë)
…RÉò¸P

•ÊŽ¢
),
¢Vû(ÍäY

Ð
IýÊ

ž,»
(0~4℃)
±
115%KCl
՜Ÿr8
ê˜Gd

Ö:²

Q–:¨

;O,»±
115%KCl
˜¤$

QI:²

¶:²LŸ,»±RST÷

ž
RS-UÖ:²V#

ÅO,»±

ºßëB
115%
KCl
±
HEPES
yÕ¤
(pH74),
,˜$%o

%o
Ÿ
4℃,9000×g
žS
20min,
<÷ª¤•
S9。
—½
ŸžS3$
,Bradford
á|}ëß
,-80℃
d

23 
|}WIÃ;q
•D;ÖH”±|}WIÃ

ìwž±WI
|}±Ã‡¨



Ýû¼Önñò—à


;Ö|}WI

24 
¶·ÒJ
241 
ìH
 
Ö
05mL
Ý¶Xð±
S9
Ÿ
37

¢˜$k«

W~c©Ö
05g·mL-1
± ¡#
Ö¤
05mL,37℃
¶·
30min,
ÅO
02mL
Ýû¼
¸0ւ

Ÿ
4℃,1500×g
žS
5min,
Ö÷ª¤
20μLÖnHPLC—à(n=3)。
242 
çƒ
 
Ö
05mLS9
Ÿ
37℃
¢˜$k
«

W~c©Ö
05g·mL-1
± ¡#Ö¤
05mL,
37℃
¶·
30min,
ÅO
02mL
Ýû¼¸0ւ

Ÿ
4℃,1500×g
žS
5min,
Ö÷ª¤
20μLÖn
HPLC
—à
(n=3)。
25 
(çÒJ
[9]

HypersilODS2
(ç”
(46mm×250mm,
5μm),‚áVË280nm,Gö1mL·min-1,”¶
30℃,
Ö#ß
20μL,G¶€01% LYm¼¢˜¤
(A)

(B),
Ö¾œü
(0~30min,2% ~34% B;
30~35min,34% ~65%B;35~50min,65% ~
100%B)。
3 
Ͼ
31 Bradford
á|}ëß
Bradford
á|}Oa©3¾

•i0Â

6
á#¤$±|}ëߕ0Â

áâ±ÂÈ.›•
Y=00055X-00079,
€Å=
R2=09963。
á
<Ë)±²
S9
#¤$|}Þßž•
22g·L-1。
·9811·
2016
y

z ³
41
ų

}
Vol41,No.7 April,2016
32 
WI|}æ¤
ìwž±WI|}±Ã‡¨



Ýû¼Ö
nñò—à

«¬Óì ¡¢#¤±òó

]q
1。
—àq

$(琱=M

WIÃì#Ö¤ò
óQ:±ÉÝû¼

Ӻɇ¨

QYÉm«

A
#Ö¤

‡¨
1∶1;B
#Ö¤


1∶1;C
#Ö¤

Ýû¼
10∶1;
D005g·mL-1
 ¡#Ö¤

q
1 
¥¦WIÍS ¡¢#¤
HPLC
q
Fig1 HPLCchromatogramsofstudiesonChuanxiongdiferent
precipitantreagents
•DÖ[ͦ¤ÅO²
S9
ýYË)#¤OW
IÃì#¤±òó

ݦ÷gœæ

;և¨¬Ý
û¼

—`¦¤Óì#¤±WIÉæ

]q
2。
”
5ì#¤O

œü†+ì#¤í
10min
$±ì
–j]

‡¨WIOL/*±•#¤_ Ô

Ý
û¼*±•-•

‰Vñò

;ÖÝû¼•|
}WIÃ

33 
²
S9
ì ¡$•–—±P›žŸ
ar,‰2qç$*+±
19
•—àì-

¥¦S±œæ]q
3。
Ó$
13,16
ìH¤
‰ô—`•K¼¬€ ¡8
I。
xS#¤
±‘2]*
1。
•~q얗P›±òóÉ
æ

ÍO9ˇ±¯Y¬x-Dó

P›‡
=(
ìH
‘2

烐‘2
)/
ìH‘2
×
100%,
Zy*i¶·Y‘2øÅ

?y*i¶·
Y‘2&ê

pžÆx[J
SPSSStatistics170
ìçƒ=>Ön´#9

‚ƒ
,P<005
•BÆ
xd0

A
‡¨
;B
Ýû¼
;C005g·mL-1
 ¡#Ö¤

q
2 
¥¦WIÃì²
S9
#¤±Sœæ
Fig2 HPLCchromatogramsofstudiesonS9incubationdifer
entprecipitantreagents
A
ìH
;B
çƒ
;C
r,

q
3 
²
S9
¶·Y#¤±
HPLC
q
Fig3 HPLCchromatogramsofsamplesafterS9incubation
Ͼhi

Ñ烀ñ


1~6,9~14,16,
17
ÑìHBh·µÔÕ
(P<001),
éú¶·í
YӐ‘2BúhøÅpü&ê

œVP›‡=y
—àM


1,2,9,11,14,16,17
¶·Y‘2ú
h&ê

éúÓ{G²
S9


§
3~6,10,12

·Y‘2h·øÅ

éú²
S9
¶·O

B–—þ
±€ßo_



烿
2921min
Od±D

¥
N1,*úӕ ¡$•–—¸² S9P›
Y–±ã˜

-°˜Þ~:ƒ‚á

4 
œs
ìU[–—±²³´µ~_O

…R¿°Ul
²ÆGÉÀ킞ÓÔ

åÑ°8çpžŸQ•
€ù±¦¤,˜©ª±œ

Ó烱ÒJьá
~,Y±²ÚÂSM²zÎ

Ñ$°±€µÕ÷

«\<è
[10]
çpžïœ«¬<ج ¡,ì±
·0911·
P^#è

²
S9
¶·«¬ ¡•–—²©ª¸¹$±²ºP›
  *1 ¶·Y#¤±‘2(珋x±s,n=3)
Table1 Theareapeakofsamplesafterincubation(珋x±s,
n=3)
<
‘2
ìH çƒ
P›‡
/%
1 36467±927 31267±6601) 1426
2 255750±3826 37171±81931) 8547
3 1111043±23672 1205758±371761) -852
4 232441±2359 266809±61281) -1479
5 185811±979 191635±27521) -313
6 252845±1670 287768±23091) -1381
7 312313±508 309285±2074 097
8 3888458±58837 3990302±13626 -262
9 905117±4470 890081±69091) 166
10 186525±1228 213180±18491) -1429
11 361944±2767 337881±16611) 665
12 47186±649 56470±13331) -1967
13 3632156±17234 3650653±17567 -051
14 193802±3026 178116±27981) 809
15 190200±37169 223717±10302 -1762
16 8444574±40348 8262017±241241) 216
17 1361777±15178 1309516±169651) 384
18 56828±24449 79653±8175 -4017
19 463319±9616 468855±5716 -119
  
å

ÑìHñò
1)P<001。
‰Â–—±²©ª



ʟ²ºì,˜±P›

€ì¿°UlÆGÉ1Ÿ²Ê8,˜±&êßÏx
-©ª±ß

²ÆG¬np¢Ž{Xç±Ö‚,
˜±©ªžŸ

9“í}¿ì<ØÛÖn
BCS
—ÄOçŠçD’[±-

¬€¯ìïĖ—Mp
ž²ÆG¬np¢PQ~_Ó³´µ

ÌYØ>
Óâ±
BCS
›
BDDCS(biopharmaceuticsdrugdispo
sitionclassificationsystem)[11]
Ön—Ä

1Ÿ$,±•–—–ë

9“#dD$,
˜,×ÄÅÆ
[12](biopharmaceuticsclassifica
tionsystemofChinesemateriamedica,CMMBCS)
±&
ñE

›æ/¶
BCS
ÍO$,•–—°Å$

ì
{G²ºP›±–—ç¥M­®±/ì³´µÖn
áâ

§•–—æ-åÓß±–ë¥M{ì|[
–—Ön°8ðçƒ

§²
S9
É[žŸ«¬²
ì,˜P›±BÉMn±œ
[13],
ÓË)€ìÁ
U

–9t

œ&D]

HVžŸÌÍ4jæ-•–
—±²P›¸¹

¦O9«¬±œæÑpž°8
«¬²Úì ¡•–—±LœæÉ[c±
[9],
Š
çD烜±M¸µ

àïnž°ð²
S9

«¬

¶,Š$•–—Ön:;—Ä

Ó$¥G²
ºP›±–—Mpž¿°Ul²ÆGáâÓ³´
µ

ÌYÖn
BCS
•Ç

§ì{G²ºP›±–—

Ë<
BDDCS,
4jHV~_Ó³´µ±çƒœ

ìÓÖn
BCS
•Çîâ

’•@[Í ¡$•–—
²³´µâµ¬âߗà#GD1i?W¬‰]


„q=

[1] AmidonGL,LennernsH,ShahVP,etal.Atheoreticalbasis
forabiopharmaceuticdrugclassification:thecorelationofinvitro
drugproductdissolutionandinvivobioavailability[J].Pharm
Res,1995,12(3):413.
[2] LiH,DongL,LiuY,etal.Comparisonoftwoapproachesofin
testinalabsorptionbypuerarin[J].JPharmacolToxicolMeth
ods,2014,70(1):6.
[3] LiH,DongL,LiuY,etal.Biopharmaceuticsclassificationof
puerarinandcomparisonofperfusionapproachesinrats[J].IntJ
Pharm,2014,466(1):133.
[4] NakamuraM,KawakitaY,YasuharaA,etal.Invitroandin
vivoevaluationofthemetabolismandbioavailabilityofesterpro
drugsofMGS0039(3(3,4dichlorobenzyloxy)2amino6flu
orobicyclo[3.1.0]hexane2,6dicarboxylicAcid),apotent
metabotropicglutamatereceptorantagonist[J].DrugMetabDis
pos,2006,34(3):369.
[5] MasakiK,HashimotoM,ImaiT.Intestinalfirstpassmetabolism
viacarboxylesteraseinratjejunumandileum[J].DrugMetab
Dispos,2007,35(7):1089.
[6] LiW,GuoJ,TangY,etal.Pharmacokineticcomparisonoffer
ulicacidinnormalandblooddeficiencyratsafteroraladministra
tionofAngelicasinensis,Ligusticumchuanxiongandtheircombi
nation[J].IntJMolSci,2012,13(3):3583.
[7] YanR,KoNL,LiSL,etal.Pharmacokineticsandmetabolism
ofligustilide,amajorbioactivecomponentinRhizomaChuanx
iong,intherat[J].DrugMetabDispos,2008,36(2):400.
[8] YanR,LinG,KoNL,etal.Loworalbioavailabilityandphar
macokineticsofsenkyunolideA,amajorbioactivecomponentin
RhizomaChuanxiong,intherat[J].TherDrugMonit,2007,29
(1):49.
[9] 


›…^



è

Œá ¡Ž-£¤…R°¤_–—
 _«¬
[J].
23$A,…k
,2008,31(5):334.
[10] 
«\<

_

<Ø ¡,ì$<ØÛ¬K¼±…R¿°
²©ªfË
[J].
A,]k
,2015,34(2):173.
[11] WuCY,BenetLZ.Predictingdrugdispositionviaapplication
ofBCS:transport/absorption/eliminationinterplayanddevelop
mentofabiopharmaceuticsdrugdispositionclassificationsystem
[J].PharmRes,2005,22(1):11.
[12] 


åK

æg

è

•–—°Å@$,˜,×Ä
ÅƱ÷€—à
[J].
$%$,-.
,2014,39(23):4479.
[13] KajbafM,RicciR,ZambonS,etal.Contributionofratintesti
nalmetabolismtothexenobioticsclearance[J].EurJDrug
MetabPharmacokinet,2013,38(1):33.

€-0
 
¤¥¥

·1911·